Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
Praxis announced FDA acceptance of NDAs for ulixacaltamide (Essential Tremor) and relutrigine (DEEs), with PDUFA target dates of January 2027 and September 2026, respectively. Elsunersen demonstrated a 77% placebo-adjusted reduction in monthly seizures in the EMBRAVE Part A study, with topline POWER1 results for vormatrigine expected in Q2 2026.
Key figures
- Net loss
- 92600000
- Rd expenses
- 78000000
- Cash balance
- $1.4 billion
- Gna expenses
- 27900000
- Pdufa relutrigine
- September 27, 2026
- Shares outstanding
- 27900000
- Pdufa ulixacaltamide
- January 29, 2027
- Seizure reduction percent
- 77%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.